A-836339
Based on 1 Customer Validation
A-836339 is a selective CB2 receptor agonist, with Ki values of 0.4 nM and 0.8 nM in humans and rats, respectively. A-836339 exhibits multiple effects such as analgesia, gastric protection, anti-inflammation, and antioxidant activity. A-836339 produces antinociceptive and analgesic activities by activating CB2 receptors in the dorsal root ganglia and spinal cord. A-836339 can also exert gastric protective effects through anti-inflammatory mechanisms (reducing TNF-α and IL-1β) and antioxidant mechanisms (enhancing the activities of CAT and SOD, and reducing H2O2). Radioactively labeled A-836339 can serve as a CB2-specific radioligand for autoradiography and PET imaging. A-836339 can be used in research on inflammatory pain, neuropathic pain, gastric ulcers, cerebral ischemia, etc.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.84%
- CAS No.: 959746-77-1
- Formule: C16H26N2O2S
- Masse moléculaire:310.45
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Neuronal Signaling Compound Library
HY-L013
-
Anti-Cancer Compound Library
HY-L025
-
Antioxidant Compound Library
HY-L037
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Targeted Diversity Library
HY-L099
-
Antidepressant Compound Library
HY-L108
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Activators Library
HY-L159
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Activité biologique
A-836339 (20 µM; 20 min; brain sections) decreases [11C]A-836339 binding in the ipsilateral hemisphere after LPS and AMPA injection[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
A-836339 (0.3 µmol/kg; i.t.) reverses neuropathic pain by acting at spinal cord sites[1].
A-836339 (0.3 µmol/kg; intra-DRG) reverses inflammatory pain by acting at dorsal root ganglion sites[1].
A-836339 (0.3 µmol/kg; intra-DRG) reverses neuropathic pain by acting at dorsal root ganglion sites[1].
A-836339 (1-10 µmol/kg; IP) reverses inflammatory pain by acting through CB2 receptors[1].
A-836339 (3-30 µmol/kg; IP) reverses neuropathic pain in the CCI model via CB2 receptor activation and without opioid dependency[1].
A-836339 (1-5 mg/kg; oral) reduces ulcer index and ULI in EtOH-induced gastric ulcer model in mice by enhancing gastroprotection and reversing histological damage, reduces TNF-α levels, and enhances antioxidant defense mechanisms by increasing CAT and SOD activities and reducing H2O2 levels[3].
A-836339 (1-5 mg/kg; oral) reduces ulcer index and ULI in NSAID-induced gastric ulcer model in mice, enhances CAT activity, and reduces H2O2 levels, while also reducing TNF-α levels[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley rats (male, 250-300 g); inflammatory model, induced by CFA injection[1]
-
Dosage:1 µmol/kg, 3 µmol/kg, 10 µmol/kg
-
Administration:IP
-
Result:Significantly reversed CFA-induced thermal hyperalgesia in a dose-dependent manner, with an ED50 of 1.8 µmol/kg. The effect was blocked by a CB2 antagonist but not a CB1 antagonist.
-
Animal Model:Sprague Dawley rats (male, 250-300 g); neuropathic model, induced by SNL[1]
-
Dosage:3 µmol/kg, 10 µmol/kg, 30 µmol/kg
-
Administration:IP
-
Result:Systemic A-836339 dose-dependently reversed SNL-induced mechanical allodynia (67% at 30 µmol/kg, ED50 14.5 µmol/kg). The effect was not blocked by naloxone.
-
Animal Model:Sprague Dawley rats (male, 250-300 g); neuropathic model, induced by CCI[1]
-
Dosage:3 µmol/kg, 10 µmol/kg, 30 µmol/kg
-
Administration:IP
-
Result:Systemic A-836339 attenuated CCI-induced mechanical allodynia (71% at 30 µmol/kg). The effect was blocked by a CB2 antagonist.
-
Animal Model:Sprague Dawley rats (male, 250-300 g); inflammatory model, induced by CFA injection[1]
-
Dosage:0.3 µmol/kg
-
Administration:Others (intra-DRG)
-
Result:Intra-DRG administration of A-836339 significantly reversed CFA-induced thermal hyperalgesia (65%).
-
Animal Model:Sprague Dawley rats (male, 250-300 g); inflammatory model, induced by CFA injection[1]
-
Dosage:0.3 µmol/kg
-
Administration:Others (i.t.)
-
Result:Intrathecal administration of A-836339 did not significantly reverse CFA-induced thermal hyperalgesia (14%).
-
Animal Model:Sprague Dawley rats (male, 250-300 g); inflammatory model, induced by CFA injection[1]
-
Dosage:0.2 µmol/kg, 0.6 µmol/kg
-
Administration:Others (i.paw)
-
Result:Ipsilateral intraplantar administration of A-836339 showed a weak effect (27% reversal at 0.6 µmol/kg), with similar effects observed on the contralateral paw.
-
Animal Model:Sprague Dawley rats (male, 250-300 g); neuropathic model, induced by SNL[1]
-
Dosage:0.3 µmol/kg
-
Administration:Others (intra-DRG)
-
Result:Intra-DRG administration of A-836339 significantly attenuated SNL-induced mechanical allodynia (45%).
-
Animal Model:Sprague Dawley rats (male, 250-300 g); neuropathic model, induced by SNL[1]
-
Dosage:0.3 µmol/kg
-
Administration:Others (i.t.)
-
Result:Intrathecal administration of A-836339 reversed SNL-induced mechanical allodynia (33%).
-
Animal Model:Balb/C mice (male, 21-23 g); EtOH-induced gastric ulcer model, induced by 80% EtOH[3]
-
Dosage:1 mg/kg, 3 mg/kg, 5 mg/kg
-
Administration:Oral
-
Result:Reduced ulcer index and ULI in a dose-dependent manner. Administration of the CB2 antagonist AM630 (1 mg/kg, i.p.) before A836339 (5 mg/kg, p.o.) significantly reversed its gastroprotective effect. Histological analysis showed reversed damage after A836339 administration. Reduced TNF-α levels compared to EtOH-treated group. Partial reversal of anti-inflammatory effect by AM630 (1 mg/kg, i.p.), though not statistically significant. IL-1β levels showed non-significant reduction. Increased catalase (CAT) and superoxide dismutase (SOD) activities in a dose-dependent manner. Reduced H2O2 levels, with the highest dose (5 mg/kg) showing statistical significance. Effects reversed by AM630 (1 mg/kg, i.p.).
-
Animal Model:Balb/C mice (male, 21-23 g); EtOH-induced gastric ulcer model, induced by 80% EtOH[3]
-
Dosage:5 mg/kg
-
Administration:Oral
-
Result:Co-localization of CB2 receptors and COX-2 in non-neuronal gastric tissue observed via immunohistochemistry (IHC).
-
Animal Model:Balb/C mice (male, 21-23 g); NSAID-induced gastric ulcer model, induced by diclofenac 30 mg/kg p.o.[3]
-
Dosage:1 mg/kg, 3 mg/kg, 5 mg/kg
-
Administration:Oral
-
Result:Reduced ulcer index and ULI in a dose-dependent manner, though differences were not statistically significant. Histological damage reversed by A836339 administration. CAT activity increased, H2O2 levels reduced. GSH levels decreased. Reduced TNF-α levels compared to NSAID-treated group. IL-1β levels showed no significant change.
Chemical Information
-
CAS No. 959746-77-1
-
Appearance Solid
-
Masse moléculaire 310.45
-
Formule C16H26N2O2S
-
Color Light yellow to yellow
-
SMILES
CC1=C(C)S/C(N1CCOC)=N\C(C2C(C)(C)C2(C)C)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvant et solubilité
DMSO : 12 mg/mL (38.65 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.71 mg/mL (2.29 mM); Clear solution
This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.1 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.71 mg/mL (2.29 mM); Clear solution
This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.1 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (287 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Hsieh GC, et al. Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol. 2011;162(2):428-440. [Content Brief]
[2]. Simmons TC, et al. Cannabinoid receptor Type 1 densities reflect social organization in Microtus. J Comp Neurol. 2021;529(5):1004-1017. [Content Brief]
[3]. Salaga M, et al. Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice. Naunyn Schmiedebergs Arch Pharmacol. 2017 Oct;390(10):1015-1027. [Content Brief]
[4]. Pottier G, et al. PET imaging of cannabinoid type 2 receptors with [11C]A-836339 did not evidence changes following neuroinflammation in rats. J Cereb Blood Flow Metab. 2017;37(3):1163-1178. [Content Brief]
[5]. Horti AG, et al. Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg Med Chem. 2010;18(14):5202-5207. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2211 mL | 16.1057 mL | 32.2113 mL | 80.5283 mL |
| 5 mM | 0.6442 mL | 3.2211 mL | 6.4423 mL | 16.1057 mL | |
| 10 mM | 0.3221 mL | 1.6106 mL | 3.2211 mL | 8.0528 mL | |
| 15 mM | 0.2147 mL | 1.0737 mL | 2.1474 mL | 5.3686 mL | |
| 20 mM | 0.1611 mL | 0.8053 mL | 1.6106 mL | 4.0264 mL | |
| 25 mM | 0.1288 mL | 0.6442 mL | 1.2885 mL | 3.2211 mL | |
| 30 mM | 0.1074 mL | 0.5369 mL | 1.0737 mL | 2.6843 mL |
A-836339 Related Classifications
HY-12761 Related Classifications
Powered by Bioz
- A-836339
- 959746-77-1
- A836339
- A 836339
- Cannabinoid Receptor
- neuropathic pain
- analgesic effects
- antinociception
- CB2
- spinal cord
- up-regulation
- positron-emission tomography (PET)
- intraplantar administration
- [11C]A-836339
- CFA
- APPswe/PS1dE9 mice
- Abeta amyloid plaque
- DRG
- endocannabinoids
- neuroinflammation
- intrathecal administration
- CB2 receptor
- positron emission tomography
- cerebral ischemia
- CB2 receptors
- lipopolysaccharide (LPS)
- [18F]DPA-714
- CB2 agonist
- intra-DRG administration
- inflammatory pain
- SNL
- quantitative RT-PCR
- mouse models
- radioligand
- paw
- cannabinoid type 2 receptors
- Alzheimer's disease
- Inhibitor
- inhibitor
- inhibit